339 related articles for article (PubMed ID: 16563625)
1. CB2 cannabinoid receptor mediation of antinociception.
Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
3. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
LaBuda CJ; Koblish M; Little PJ
Eur J Pharmacol; 2005 Dec; 527(1-3):172-4. PubMed ID: 16316653
[TBL] [Abstract][Full Text] [Related]
5. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
Beltramo M; Bernardini N; Bertorelli R; Campanella M; Nicolussi E; Fredduzzi S; Reggiani A
Eur J Neurosci; 2006 Mar; 23(6):1530-8. PubMed ID: 16553616
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors.
Guindon J; LoVerme J; Piomelli D; Beaulieu P
Anesth Analg; 2007 Jun; 104(6):1563-9, table of contents. PubMed ID: 17513659
[TBL] [Abstract][Full Text] [Related]
7. CB2 cannabinoid receptor-mediated peripheral antinociception.
Malan PT; Ibrahim MM; Deng H; Liu Q; Mata HP; Vanderah T; Porreca F; Makriyannis A
Pain; 2001 Sep; 93(3):239-245. PubMed ID: 11514083
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
Quartilho A; Mata HP; Ibrahim MM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
Anesthesiology; 2003 Oct; 99(4):955-60. PubMed ID: 14508331
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
10. Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception.
Ahn DK; Choi HS; Yeo SP; Woo YW; Lee MK; Yang GY; Jeon HJ; Park JS; Mokha SS
Pain; 2007 Nov; 132(1-2):23-32. PubMed ID: 17321048
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.
Rahn EJ; Zvonok AM; Makriyannis A; Hohmann AG
AAPS J; 2010 Jun; 12(2):147-57. PubMed ID: 20127295
[TBL] [Abstract][Full Text] [Related]
12. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
Hohmann AG; Farthing JN; Zvonok AM; Makriyannis A
J Pharmacol Exp Ther; 2004 Feb; 308(2):446-53. PubMed ID: 14610224
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
14. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
[TBL] [Abstract][Full Text] [Related]
16. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
17. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.
Ibrahim MM; Porreca F; Lai J; Albrecht PJ; Rice FL; Khodorova A; Davar G; Makriyannis A; Vanderah TW; Mata HP; Malan TP
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):3093-8. PubMed ID: 15705714
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR
Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
